Maxwell Skor
Stock Analyst at Morgan Stanley
(4.80)
# 498
Out of 4,575 analysts
217
Total ratings
73.7%
Success rate
28.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Rated: Buy | $103 | $80.74 | +27.57% | 21 | Jul 23, 2026 | |
| INSM Insmed | Maintained: Buy | $212 | $106.92 | +98.28% | 23 | Jul 23, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $256 → $275 | $253.86 | +8.33% | 23 | Jul 23, 2026 | |
| MNPR Monopar Therapeutics | Maintained: Buy | $115 | $109.87 | +4.67% | 3 | Jul 22, 2026 | |
| PHVS Pharvaris | Rated: Buy | $41 → $46 | $34.17 | +34.62% | 85 | Jun 25, 2026 | |
| TCRX TScan Therapeutics | Maintained: Hold | n/a | $0.794 | - | 6 | Jun 22, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $87 → $80 | $83.73 | -4.45% | 7 | Jun 15, 2026 | |
| CRSP CRISPR Therapeutics AG | Upgraded: Hold | $60 | $46.54 | +28.92% | 1 | Jun 11, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Hold | $12 | $3.87 | +210.08% | 8 | May 18, 2026 | |
| AVIR Atea Pharmaceuticals | Maintained: Hold | $6 | $4.73 | +26.85% | 9 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $3.18 | +277.36% | 3 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $26.90 | +149.07% | 11 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.20 | - | 6 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9.5 → $3.55 | $0.6114 | n/a | 10 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.25 | $0.602 | n/a | 1 | Sep 25, 2023 |
Cytokinetics
Jul 23, 2026
Rated: Buy
Price Target: $103
Current: $80.74
Upside: +27.57%
Insmed
Jul 23, 2026
Maintained: Buy
Price Target: $212
Current: $106.92
Upside: +98.28%
Ascendis Pharma
Jul 23, 2026
Maintained: Buy
Price Target: $256 → $275
Current: $253.86
Upside: +8.33%
Monopar Therapeutics
Jul 22, 2026
Maintained: Buy
Price Target: $115
Current: $109.87
Upside: +4.67%
Pharvaris
Jun 25, 2026
Rated: Buy
Price Target: $41 → $46
Current: $34.17
Upside: +34.62%
TScan Therapeutics
Jun 22, 2026
Maintained: Hold
Price Target: n/a
Current: $0.794
Upside: -
Crinetics Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $87 → $80
Current: $83.73
Upside: -4.45%
CRISPR Therapeutics AG
Jun 11, 2026
Upgraded: Hold
Price Target: $60
Current: $46.54
Upside: +28.92%
Bicycle Therapeutics
May 18, 2026
Maintained: Hold
Price Target: $12
Current: $3.87
Upside: +210.08%
Atea Pharmaceuticals
May 18, 2026
Maintained: Hold
Price Target: $6
Current: $4.73
Upside: +26.85%
May 18, 2026
Maintained: Buy
Price Target: $12
Current: $3.18
Upside: +277.36%
May 6, 2026
Maintained: Buy
Price Target: $67
Current: $26.90
Upside: +149.07%
Aug 22, 2025
Maintained: Hold
Price Target: n/a
Current: $3.20
Upside: -
Nov 20, 2024
Maintained: Buy
Price Target: $9.5 → $3.55
Current: $0.6114
Upside: n/a
Sep 25, 2023
Downgraded: Hold
Price Target: $3.25
Current: $0.602
Upside: n/a